The Power of Real World Data to Study Women’s Health at Scale

Why It Matters

The report provides actionable insights for clinicians, payers, and pharma, enabling more precise interventions for women’s chronic conditions, a historically under‑researched segment.

Key Takeaways

• Real‑world data reveals distinct disease patterns across female life stages
• Women face higher chronic condition prevalence despite longer life expectancy
• Report links EHRs with claims to capture comprehensive treatment trends
• Findings can guide targeted therapies and inform policy investment

Pulse Analysis

Real‑world data has become a cornerstone for uncovering health trends that traditional clinical trials often miss, especially in populations that receive less research attention. Women’s health exemplifies this gap: despite living longer than men, U.S. women experience higher rates of chronic illnesses, yet federal and private funding remain modest. Large, de‑identified datasets that combine electronic health records with insurance claims can illuminate the nuanced interplay of biology, hormones, and social factors across a woman’s lifespan, offering a richer picture than isolated studies.

Veradigm’s 2026 Women’s Health Report showcases a robust methodology that merges longitudinal EHR information with administrative claims, creating a comprehensive view of diagnosis, treatment, and outcomes. This linkage allows analysts to track comorbidity clusters, prescription patterns, and preventive‑care utilization in real time. For example, the data reveal how menopause‑related hormonal shifts intersect with cardiovascular risk, or how adolescent mental‑health diagnoses influence later chronic disease trajectories. Such granular insights are impossible to capture through surveys alone and provide a scalable template for future gender‑focused research.

The implications extend across the healthcare ecosystem. Pharmaceutical firms can identify unmet therapeutic needs and design gender‑specific trials, insurers can refine risk models and preventive‑care incentives, and policymakers gain evidence to justify increased investment in women’s health programs. As real‑world evidence continues to mature, the ability to personalize care pathways for women will likely improve outcomes, reduce costs, and close longstanding research gaps. Stakeholders that act on these data‑driven insights will position themselves at the forefront of a more equitable and efficient health market.